Bolt Biotherapeutics, Inc. Common Stock (BOLT)
Bolt Biotherapeutics, Inc. is a biotechnology company focused on developing tumor-activated immunotherapies. They utilize their proprietary Amplify-They-Cell platform to design therapies that activate the immune system specifically within the tumor microenvironment, aiming to enhance cancer treatment efficacy while minimizing systemic side effects.
Company News
Bolt Biotherapeutics announced positive results from a Phase 1 study of its cancer immunotherapy BDC-3042, which showed favorable safety, biological activity, and signs of anti-tumor activity. The company is seeking a partner to advance the development of BDC-3042.
Bolt Biotherapeutics, a pharmaceutical company, has been notified by Nasdaq of non-compliance with the exchange's minimum bid price requirement. The company has been given a grace period to regain compliance, but if it fails to do so, its stock could be delisted from the exchange.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Deutsche Bank analyst Bryan Keane downgraded the rating on Accenture plc (NYSE:ACN) from Buy to Hold, while slashing the price target from $409 to $295. Accenture shares declined 0.2% to close at $306.95 on Tuesday. See how other analysts view this stock. Stifel analyst Stephen Willey downgraded Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) from Buy to Hold and lowered the price target from $6 to $1.5. Bolt Biotherapeutics shares slipped ...Full story available on Benzinga.com
Prothena (PRTA) delivered earnings and revenue surprises of -10.74% and 98.67%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Are these hot penny stocks on your list right now? The post Hot Penny Stocks to Watch Now? 3 For Your List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.